Infinity Pharmaceuticals PT Raised to $15.00 at Jefferies Group (INFI)
Equities research analysts at Jefferies Group lifted their price objective on shares of Infinity Pharmaceuticals (NASDAQ:INFI) from $13.00 to $15.00 in a research note issued to investors on Wednesday, American Banking News reports. Jefferies Group’s price target points to a potential downside of 7.12% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Nomura initiated coverage on shares of Infinity Pharmaceuticals in a research note on Wednesday, January 8th. They set a “neutral” rating on the stock. Analysts at Credit Suisse downgraded shares of Infinity Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Thursday, December 12th. They now have a $20.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Infinity Pharmaceuticals currently has an average rating of “Hold” and an average target price of $28.67.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) traded up 2.23% during mid-day trading on Wednesday, hitting $16.51. The stock had a trading volume of 1,108,728 shares. Infinity Pharmaceuticals has a 52-week low of $11.30 and a 52-week high of $50.51. The stock has a 50-day moving average of $13. and a 200-day moving average of $15.16. The company’s market cap is $793.9 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Tuesday, February 25th. The company reported ($0.68) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.87) by $0.19. On average, analysts predict that Infinity Pharmaceuticals will post $-3.15 earnings per share for the current fiscal year.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.